The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer.
Ferenc G. Rick
No relevant relationships to disclose
Cale D. Fahrenholtz
No relevant relationships to disclose
Maria I. Garcia
No relevant relationships to disclose
Norman L. Block
No relevant relationships to disclose
Andrew V. Schally
No relevant relationships to disclose
Kerry L. Burnstein
No relevant relationships to disclose